{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:58:06Z","timestamp":1787025486016,"version":"build-2736575974"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.2967\/jnumed.122.264342","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:45:52Z","timestamp":1663865152000},"page":"372-378","source":"Crossref","is-referenced-by-count":16,"title":["PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study"],"prefix":"10.2967","volume":"64","author":[{"given":"Caner","family":"Civan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Fragoso-Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pogorzelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt Michael","family":"Schaarschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"L\u00fcckerath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"2023033021451405000_64.3.372.1","unstructured":"El-Naggar AK Chan JKC Grandis JR Takata T Slootweg PJ, eds . WHO Classification of Head and Neck Tumours. International Agency for Research on Cancer; 2017:162\u2013185."},{"key":"2023033021451405000_64.3.372.2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejca.2020.01.023","article-title":"A prospective multicentre REFCOR study of 470 cases of head and neck adenoid cystic carcinoma: epidemiology and prognostic factors","volume":"130","author":"Atallah","year":"2020","journal-title":"Eur J Cancer."},{"key":"2023033021451405000_64.3.372.3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12070-014-0755-x","article-title":"Clinicopathological review and survival characteristics of adenoid cystic carcinoma","volume":"67","author":"Binesh","year":"2015","journal-title":"Indian J Otolaryngol Head Neck Surg."},{"key":"2023033021451405000_64.3.372.4","doi-asserted-by":"crossref","first-page":"105213","DOI":"10.1016\/j.oraloncology.2021.105213","article-title":"Prognosis and management of recurrent and\/or metastatic head and neck adenoid cystic carcinoma","volume":"115","author":"Lorini","year":"2021","journal-title":"Oral Oncol."},{"key":"2023033021451405000_64.3.372.5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0026"},{"key":"2023033021451405000_64.3.372.6","doi-asserted-by":"crossref","unstructured":"Kang EJ Ahn MJ Ock CY . Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma. Clin Cancer Res. 202;27:5272\u20135279.","DOI":"10.1158\/1078-0432.CCR-21-1061"},{"key":"2023033021451405000_64.3.372.7","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol."},{"key":"2023033021451405000_64.3.372.8","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol."},{"key":"2023033021451405000_64.3.372.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"2023033021451405000_64.3.372.10","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.18632\/oncotarget.13952","article-title":"Management of salivary gland carcinomas: a review","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget."},{"key":"2023033021451405000_64.3.372.11","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3890-4"},{"key":"2023033021451405000_64.3.372.12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13139-016-0445-6","article-title":"68Ga-PSMA PET-CT imaging of metastatic adenoid cystic carcinoma","volume":"51","author":"De Keizer","year":"2017","journal-title":"Nucl Med Mol Imaging."},{"key":"2023033021451405000_64.3.372.13","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.7150\/thno.38501","article-title":"68Ga-PSMA-HBED-CC PET\/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study","volume":"10","author":"van Boxtel","year":"2020","journal-title":"Theranostics."},{"key":"2023033021451405000_64.3.372.14","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s00259-017-3737-x","article-title":"Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma: a preliminary analysis","volume":"44","author":"Klein Nulent","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023033021451405000_64.3.372.15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/RLU.0000000000002645","article-title":"Radionuclide therapy with 177Lu-PSMA in a case of metastatic adenoid cystic carcinoma of the parotid","volume":"44","author":"Has Simsek","year":"2019","journal-title":"Clin Nucl Med."},{"key":"2023033021451405000_64.3.372.16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","article-title":"68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging\u2014version 1.0","volume":"44","author":"Fendler","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023033021451405000_64.3.372.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.198119"},{"key":"2023033021451405000_64.3.372.18","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023033021451405000_64.3.372.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2023033021451405000_64.3.372.20","unstructured":"Common terminology criteria for adverse events (CTCAE), version 5.0. Cancer Therapy Evaluation Program website. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Published November 27, 2017. Accessed December 15, 2022."},{"key":"2023033021451405000_64.3.372.21","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"key":"2023033021451405000_64.3.372.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.211094"},{"key":"2023033021451405000_64.3.372.23","doi-asserted-by":"publisher","DOI":"10.1002\/hed.25485"},{"key":"2023033021451405000_64.3.372.24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00432-021-03518-5","article-title":"Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer","volume":"147","author":"Franzese","year":"2021","journal-title":"J Cancer Res Clin Oncol."},{"key":"2023033021451405000_64.3.372.25","doi-asserted-by":"publisher","DOI":"10.1006\/geno.2000.6446"},{"key":"2023033021451405000_64.3.372.26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","article-title":"Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges","volume":"51","author":"Bakht","year":"2017","journal-title":"Nucl Med Mol Imaging."},{"key":"2023033021451405000_64.3.372.27","doi-asserted-by":"crossref","first-page":"105018","DOI":"10.1016\/j.oraloncology.2020.105018","article-title":"Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2020","journal-title":"Oral Oncol."},{"key":"2023033021451405000_64.3.372.28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13550-021-00866-8","article-title":"First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer","volume":"11","author":"Klein Nulent","year":"2021","journal-title":"EJNMMI Res."},{"key":"2023033021451405000_64.3.372.29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.207704"},{"key":"2023033021451405000_64.3.372.30","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1007\/s00259-021-05433-w","article-title":"PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports","volume":"48","author":"Uijen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.122.264342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:47:31Z","timestamp":1680223651000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.122.264342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3,2]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.2967\/jnumed.122.264342"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.122.264342","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}